ImmunityBio, Inc.
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $44.21M | $-0.62 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 15, 2026 | Before market open | $38.30M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $26.40M | $-0.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 15, 2025 | Before market open | $16.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 14, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Dec 12, 2022 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Sep 13, 2021 | Before market open | – | – | – |
Press releases
Announcements ImmunityBio filed with the SEC
FDA Expands ANKTIVA ® Approval
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million,
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Receives United Arab Emirates (UAE) Marketing
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Receives Authorization from the European Commission
Other events · EX-99.1 to Form 8-K
ImmunityBio Reports Continued Execution and Sales
Results of operations · EX-99.1 to Form 8-K
Saudi FDA Grants Accelerated Approval to ImmunityBio’s
Other events · EX-99.1 to Form 8-K
Saudi FDA Grants Accelerated Approval to ImmunityBio’s
Other events · EX-99.2 to Form 8-K
ImmunityBio Receives Conditional Marketing Authorization
Other events · EX-99.1 to Form 8-K
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth
Results of operations · EX-99.1 to Form 8-K
Judge: Hon. Gonzalo P. Curiel
Other events · EX-99.1 to Form 8-K
Judge: Hon. Gonzalo P. Curiel
Other events · EX-99.2 to Form 8-K
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025,
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025,
Results of operations · EX-99.1 to Form 8-K
IMMUNITYBIO REQUESTS AN URGENT MEETING WITH FDA TO ADDRESS THE CHANGE
Other events · EX-99.1 to Form 8-K
ImmunityBio Announces FDA Submissions of Supplemental BLA for
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Results of operations · EX-99.1 to Form 8-K
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100 th Patient in
Other events · EX-99.1 to Form 8-K
ImmunityBio Reports Third-Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ImmunityBio Announces $320 Million Investment by Oberland
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ImmunityBio Announces $470 Million Equity and Debt Financing
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
enrollment and results, the regulatory review process and timing 11/14/202 2 thereof, timing of regulatory submissions, timing of meetings with regulators, potential implications to be drawn from clinical trials, potential commercialization of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K